“Clinical Aspects” Of Wyeth’s Lybrel To Be Publicly Reviewed After “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Data on bleeding patterns, pregnancy rates and discontinuations for the continuous oral contraceptive will be discussed.
You may also be interested in...
Lybrel To Launch In July Following FDA Approval
Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.
Lybrel To Launch In July Following FDA Approval
Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Manufacturing facility concerns likely will derail approval of the oral contraceptive and the antidepressant before the end of the year.